Skip to main content
Sunshine Lake Pharma Co., Ltd. logo

Sunshine Lake Pharma Co., Ltd. — Investor Relations & Filings

Ticker · 6887 ISIN · CNE1000070M8 HKEX Manufacturing
Open in API
Filings indexed 79 across all filing types
Latest filing 2026-05-22 Share Issue/Capital Cha…
Country HK Hong Kong
Listing HKEX 6887

About Sunshine Lake Pharma Co., Ltd.

https://www.hecpharm.com

Sunshine Lake Pharma Co., Ltd. is a research-based, vertically integrated pharmaceutical company engaged in the R&D, production, and commercialization of innovative pharmaceutical products. Its core therapeutic focus areas include infectious diseases, chronic diseases, and oncology, with pipeline assets also targeting conditions such as psoriasis and rheumatoid arthritis. The company emphasizes the globalization and accelerated commercialization of its innovative drug portfolio. To enhance its R&D capabilities, Sunshine Lake Pharma utilizes advanced technology platforms, notably through strategic investments in joint ventures focused on AI and robotics for drug discovery. It also participates in the sourcing and supply of pharmaceutical and animal health ingredients.

Recent filings

Filing Released Lang Actions
Next Day Disclosure Return
Share Issue/Capital Change Classification · 90% confidence The document is a Hong Kong Exchange (HKEX) FF305 Next Day Disclosure Return reporting changes in issued shares (conversion of domestic shares into H shares) and the related share capital balances. It is a regulatory announcement of share capital changes rather than the share issuance report itself or an earnings report. This matches the definition for Share Issue/Capital Change.
2026-05-22 English
INSIDE INFORMATION COMPLETION OF THE H SHARE FULL CIRCULATION
Share Issue/Capital Change Classification · 85% confidence The document is an "Inside Information" announcement made under HKEX Listing Rules. It describes the completion of conversion of domestic shares into H shares and the commencement of listing of the converted shares, including before-and-after shareholding structure. This is not a financial report, earnings release, or general notice; it is an announcement of a capital structure change (new share conversion and listing). Therefore, it fits the Share Issue/Capital Change category.
2026-05-21 English
INSIDE INFORMATION LISTING APPROVAL GRANTED BY THE STOCK EXCHANGE IN RESPECT OF THE H SHARE FULL CIRCULATION
Capital/Financing Update Classification · 95% confidence The document is an announcement from Sunshine Lake Pharma Co., Ltd. regarding the approval granted by the Stock Exchange for the listing and trading of converted H Shares from Domestic Shares. It details the shareholding structure before and after the conversion and listing, including the number of shares and percentages held by various shareholders. The document is titled as an "Inside Information" announcement and references compliance with listing rules and inside information provisions. It does not contain financial statements, audit information, or detailed financial results. It is not a report but an official announcement about a capital structure change related to share conversion and listing approval. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is sufficient and contains substantive information about the capital change, not merely a brief notification or a report publication announcement.
2026-05-06 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2026
Regulatory Filings Classification · 95% confidence The document is a monthly return filing to the Hong Kong Exchanges and Clearing Limited (HKEX) regarding movements in securities for Sunshine Lake Pharma Co., Ltd. It details movements in authorized and issued shares, treasury shares, public float sufficiency confirmation, and share repurchase activities. The document is structured as a regulatory compliance report under HKEX rules, specifically referencing Chapter 19B of the Exchange Listing Rules. It is not a financial report, earnings release, or management discussion, but a regulatory filing about share capital and share movements. The document length is over 10,000 characters and contains detailed data on share capital movements and repurchases, consistent with a regulatory filing rather than a report publication announcement or a financial report. Therefore, the appropriate classification is Regulatory Filings (RNS).
2026-05-06 English
VOLUNTARY ANNOUNCEMENT IN RELATION TO THE MARKETING APPROVAL OF INSULIN GLARGINE INJECTION BY THE U.S. FOOD AND DRUG ADMINISTRATION (FDA)
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Sunshine Lake Pharma Co., Ltd. regarding the FDA marketing approval of their Insulin Glargine Injection product. It provides detailed information about the drug, clinical trial results, market potential, and the company's global strategy. The document is an announcement of a business development event rather than a financial report, regulatory filing, or management discussion. It does not contain financial statements, audit information, or voting results. It is not a report publication announcement since it does not mention the release or availability of a report. The content fits best under a general regulatory or business update announcement category. Given the available categories, the closest fit is Regulatory Filings (RNS), which serves as a fallback for miscellaneous announcements that do not fit other specific categories.
2026-05-04 English
2025 Environmental, Social and Governance Report
Environmental & Social Information Classification · 100% confidence The document is titled '2025 Environmental, Social And Governance Report' and contains extensive content related to environmental, social, and governance (ESG) topics such as responsible governance, quality, green development, safe production, people-oriented policies, and social contributions. It references compliance with ESG reporting guidelines from the Hong Kong Stock Exchange and other standards. The report covers the full year 2025 and is approved by the Board of Directors. It explicitly states it is an ESG report and is published annually. There is no indication that this is a financial report, audit report, or any other type of filing. The content aligns with the definition of Environmental & Social Information (SR), which details the company's performance on ESG factors.
2026-04-30 English

Browse filings by year

2 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.